{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:48Z","timestamp":1782534468656,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with end-stage renal disease (ESRD) are characterized with high risk of heart failure. Although mineralocorticoid receptor antagonists have beneficial effect on relieving cardiac fibrosis and, thus, reduce the incidence of cardiovascular disease and cardiac death, the therapeutic benefits and adverse effects are still controversial. We conducted a meta-analysis to measure the safety and efficacy of spironolactone in patients undergoing dialysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search for randomized controlled trials (RCTs) was performed in PubMed, Embase, and Cochrane databases. Primary outcomes included changes in all-cause mortality (ACM), serum potassium concentration, incidence of hyperkalemia and gynecomastia (GYN). Secondary outcomes included changes in blood pressure (BP), left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF). Subgroup analysis and sensitivity analysis were further conducted. This research was registered with PROSPERO (International Prospective Register of Systematic Reviews; No. CRD42021287493).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen RCTs with 1,258 patients were enrolled in this pooled-analysis. Spironolactone treatment significantly decreased ACM (RR = 0.42, <jats:italic>P<\/jats:italic> &amp;lt; 0.0001), CCV (RR = 0.54, <jats:italic>P<\/jats:italic> = 0.008) and LVMI (MD = \u22126.28, <jats:italic>P<\/jats:italic> = 0.002), also increased occurrence of GYN (RR = 4.36, <jats:italic>P<\/jats:italic> = 0.0005). However, LVEF (MD = 2.63, <jats:italic>P<\/jats:italic> = 0.05), systolic BP (MD = \u22124.61, <jats:italic>P<\/jats:italic> = 0.14) and diastolic BP (MD = \u22120.12, <jats:italic>P<\/jats:italic> = 0.94) did not change between two groups after treatment. Although serum potassium concentration was increased (MD = 0.22, <jats:italic>P<\/jats:italic> &amp;lt; 0.0001) after spironolactone supplement, the risk of hyperkalemia remained unchanged (RR = 1.21, <jats:italic>P<\/jats:italic> = 0.31). Further subgroup analysis found more obvious advantageous as well as disadvantageous effects in Asian subjects than European or American ones. Also, with more than 9 months of treatment duration, patients achieved more favorable influence than shorter duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results highlight the therapeutic effects of spironolactone on cardiovascular indexes, including ACM, CCV, and LVMI. However, the unignorable increase of GYN incidence and serum potassium level indicate that close monitor in dialysis-dependent patients, especially Asian patients, is essential.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.828189","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T13:21:55Z","timestamp":1647523315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WanYu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41581-019-0154-3","article-title":"Cardiovascular disease in young adults with incident ESRD","volume":"15","author":"Ku","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJM199809173391203","article-title":"Poor long-term survival after acute myocardial infarction among patients on long-term dialysis","volume":"339","author":"Herzog","year":"1998","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0272-6386(95)90492-1","article-title":"Hypertension in the hemodialysis population: a survey of 649 patients","volume":"2","author":"Salem","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone-and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub3","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/HJH.0b013e32835f955c","article-title":"Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients","volume":"31","author":"Flevari","year":"2013","journal-title":"Am J Hypertens"},{"key":"B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J Clin Hypertens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2147\/DDDT.S189454","article-title":"Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1925243","DOI":"10.1155\/2019\/1925243","article-title":"Aldosterone antagonists reduce the risk of cardiovascular mortality in dialysis patients: a meta-analysis","volume":"2019","author":"Li","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/epi.13989","article-title":"Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life","volume":"59","author":"Michaelis","year":"2018","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J Clin Hypertens"},{"key":"B16","first-page":"1303","article-title":"Effects of spironolacone on cardiac and residual renal function in patients with peritoneal dialysis","volume":"16","author":"Wang","year":"2018","journal-title":"Chinese Gen. Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/clc.20838","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B22","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1161\/01.HYP.0000015905.27598.E9","article-title":"Aldosterone is produced from ventricles in patients with essential hypertension","volume":"39","author":"Yamamoto","year":"2002","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000245635","article-title":"Aldosterone in uremia\u2013beyond blood pressure","volume":"29","author":"Ritz","year":"2010","journal-title":"Blood Purif"},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 \u03b2","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/hr.2011.220","article-title":"Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats","volume":"35","author":"Nakagaki","year":"2012","journal-title":"Hypertens Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/ki.2009.35","article-title":"Left ventricular hypertrophy in renal disease: beyond preload and afterload","volume":"75","author":"Ritz","year":"2009","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2147\/DDDT.S100095","article-title":"Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats","volume":"10","author":"Zhou","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/labinvest.2014.69","article-title":"The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis","volume":"94","author":"Zhang","year":"2014","journal-title":"Lab Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0272-6386(85)80022-6","article-title":"Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis","volume":"6","author":"Spital","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.ajkd.2005.03.015","article-title":"Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication","volume":"46","author":"Szeto","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0002-9149(99)80703-6","volume":"75","author":"Woo","year":"1995","journal-title":"Am J Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"17253","DOI":"10.1038\/srep17253","article-title":"SLCO1B1 variants and angiotensin converting enzyme inhibitor (enalapril)-induced cough: a pharmacogenetic study","volume":"5","author":"Luo","year":"2015","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e003529","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"CD009120","DOI":"10.1002\/14651858.CD009120.pub2","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients","volume":"23","author":"Zhang","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.kint.2018.12.006","article-title":"The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward","volume":"95","author":"Rossignol","year":"2019","journal-title":"Kidney Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12944-020-01204-y","article-title":"Dyslipidemia and cardiovascular disease risk among the MASHAD study population","volume":"19","author":"Hedayatnia","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.828189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T13:22:00Z","timestamp":1647523320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.828189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":46,"alternative-id":["10.3389\/fmed.2022.828189"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.828189","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"828189"}}